Grand Rounds, September 25, 2025


September 25, 2025

Presentation Title: Congenital Diaphragmatic Hernia – The Last 75 Years

Speakers: Kevin Lally, MD


Date: Thursday, September 25, 2025
Time: 7:00 AM ‐ 8:00 AM
Location: Medical School Building
Learning Format: In‐Person


Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Describe the 3 major changes in management of CDH over the past 75 years
  • List the most important predictors of severity in CDH
  • Explain the role of fetal intervention in patients with CDH

Credit Designation:

  • McGovern Medical School at the University of Texas Health Science Center at Houston designates this live activity for a maximum of 1 AMA PRA Category 1Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • McGovern Medical School at the University of Texas Health Science Center at Houston designates this live activity for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Event Disclosures:

Speakers:
Kevin Lally, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Planners and other Administrative Support:
David Wainwright, MD, Sasha Adams, MD, Associate Professor, Acute Care Surgery Program Director, General Surgery Residency Vice-Chair for Education, Department of Surgery, Lillian Kao, MD, Professor, Surgery, Natalie Drucker, MD, and Tamara Saunders, MD have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re selling, or distributing healthcare products used by or on patients to disclose.

Mark Hobeika, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re­selling, or distributing healthcare products used by or on patients:

  • TransMedics, Inc – Contracted Research – Relationship Ended

Steven Canfield, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re­selling, or distributing healthcare products used by or on patients:

  • AngioDynamics – Advisory Committee Member – Relationship Has Not Ended

Erik Wilson, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Johnson & Johnson – Teaching – Relationship Has Not Ended
  • Gore – Teaching – Relationship Has Not Ended
  • Medtronic – Teaching – Relationship Has Not Ended
  • GI Windows – Independent Contractor – Relationship Has Not Ended
  • Boston Scientific – Teaching – Relationship Has Not Ended

Laura Moore, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Frontline Medical Technologies – Advisory Committee Member – Relationship Has Not Ended

Shinil Shah, DO has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • GI Windows – Contracted Research – Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.


Commercial Support:
This activity is not commercially supported.


Accreditation Statement:
McGovern Medical School at the University of Texas Health Science Center at Houston is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.



Related topics